hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
=== Ajinomoto === In 2004, the market for aspartame, in which Ajinomoto, the world's largest aspartame manufacturer, had a 40% share, was 14,000 metric tons (15,000 short tons; 14,000 long tons) a year, and consumption of the product was rising by 2% a year. Ajinomoto acquired its aspartame business in 2000 from Monsanto for $67 million (equivalent to $116 million in 2024). In 2007, Asda was the first British supermarket chain to remove all artificial flavorings and colors in its store brand foods. In 2008, Ajinomoto sued Asda, part of Walmart, for a malicious falsehood action concerning its aspartame product when the substance was listed as excluded from the chain's product line, along with other "nasties". In July 2009, a British court ruled in favor of Asda. In June 2010, an appeals court reversed the decision, allowing Ajinomoto to pursue a case against Asda to protect aspartame's reputation. Asda said that it would continue to use the term "no nasties" on its own-label products, but the suit was settled in 2011 with Asda choosing to remove references to aspartame from its packaging. In November 2009, Ajinomoto announced a new brand name for its aspartame sweetener – AminoSweet.
Gary Keith Ackers (1939–2011) was Emeritus Professor of Biochemistry and Molecular Biophysics of Washington University School of Medicine. His research focused on thermodynamic linkage analysis of biological macromolecules, addressing the molecular mechanism of cooperative O2 binding to human hemoglobin since the early 1970s. He was a Fellow of the Biophysical Society and one of the founders of the annual Gibbs Conference. Ackers invented agarose gel chromatography when he was a teenager. He went on the develop analytical gel chromatography methods for determinations of many important characteristics of water-soluble proteins; diffusion coefficient, molecular size, thermodynamics of protein-protein interactions including important changes due to single amino acid substitutions.
A more recent preparation method pioneered by the Royal Ontario Museum removes all bones for a complete skeleton while also producing a round skin without bill or legs (called a ROM, though if one set of wing and leg bones remain with the skin the preparation is called a shmoo in North America). Alternatively, the entire bird (or any soft parts associated with preparations described above) may be preserved in alcohol. For any of these methods, several supplemental preparations may be made. For example, a wing may be removed and preserved separately as a spread wing for better study of flight feathers; a tissue sample may be removed and frozen for molecular analyses; or a recording of the bird's song before collection may be archived. Neither molecular samples nor sound recordings require a bird to be collected (killed). Finally, if the bird is too rotten for the skin and feathers to be preserved, as is the case with some salvaged specimens, the skeleton alone may be preserved. Dried tissue is removed from skeletons by using dermestid beetle larvae (genus Dermestes). Whereas in the past arsenic was routinely added to skins to protect them from destruction by insects, specimens prepared today are generally protected by an initial freezing period to kill insects and their eggs followed by keeping them in high-quality museum cases in a climate-controlled room. Each specimen has data associated with it, and the amount of data available is usually directly correlated with the specimen's scientific value.
Sources: en.wikipedia.org
Kennedy said, "This idea is simple: If you have been convicted of a felony like bribery, extortion, embezzlement or tax evasion, you should have to disclose that when registering to become a lobbyist. Political leaders and businesses need to know the backgrounds of those who are trying to influence public policy." The bill passed the Senate on December 20, 2018, and was signed into law in 2019. In February 2020, JACK Act disclosures revealed that lobbyists with criminal histories collected $3.1 million. Leading up to the 2019 election, Kennedy was mentioned as a prospective candidate for governor in the jungle primary against incumbent John Bel Edwards, but on December 3, 2018, he said he preferred to remain in the Senate and would not run for governor.
=== Expansion === Due to the success of the Selous Scouts, Walls directed in mid-1974 that it be expanded from three to six troops. This process was completed by December 1974, and included 50 former insurgents being added to the unit. A Reconnaissance Troop was formed in the second half of 1976 to conduct scouting operations in Mozambique and Zambia; this unit had a peak strength of twelve men. As part of the expansion of the Selous Scouts, the Rhodesian Army's Tracking Wing and Tracker Combat Unit were merged into it during 1974. The Tracking Wing became the Selous Scouts' Training Troop. The Selous Scouts continued to deliver training in tracking and trackers for the remainder of the war, with this forming a cover for the unit's actual role. The Tracker Combat Unit was made up of white reservists; while these men were not suitable for Selous Scouts operations, they were retained to help provide cover. These changes reduced the effectiveness of the Rhodesian Army's tracking capabilities. The size of the Selous Scouts increased further over time, and eventually reached 1,800 men. Many of these were territorial soldiers who were not permanently attached. The rapid expansion of the Selous Scouts led to a drop in the quality of its personnel, which reduced the effectiveness of pseudo operations. This in turn caused the unit to increasingly undertake offensive operations where it directly attacked insurgents rather than gathered intelligence on them.
Selenium compounds commonly exist in the oxidation states −2, +2, +4, and +6. It is a nonmetal (more rarely considered a metalloid) with properties that are intermediate between the elements above and below in the periodic table, sulfur and tellurium, and also has similarities to arsenic.
THC is widely used as a recreational drug, both by itself or with other cannabinoids like cannabidiol (CBD) or in the form of cannabis. It is the main psychoactive constituent in cannabis. The effects of THC include euphoria, appetite stimulation, sedation, cognitive and memory impairment, pain relief, anxiety, and reduced body temperature. THC can produce strong hallucinogenic effects, mystical experiences, and psychosis-like reactions at high doses in a subset of individuals. These hallucinogenic effects are distinct from but potentially just as strong as or even stronger than those of other hallucinogens like serotonergic psychedelics, dissociatives, and salvia. Besides the hallucinogenic effects, high doses of THC can also produce effects including anxiety, panic, paranoia, delusions, heavy sedation, and catalepsy. Strong THC exposures and associated hallucinogenic and aversive effects have been especially associated with cannabis edibles.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.